| Symbol |
JAG1 |
| Full Name |
Jagged 1 (Notch Ligand) |
| Chromosome |
20p12.2 |
| NCBI Gene |
1950 |
| Ensembl |
ENSG00000101384 |
| OMIM |
184756 |
| UniProt |
P78504 |
| Protein Length |
1,218 amino acids |
| Molecular Weight |
~134 kDa |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers), Alagille Syndrome, Deafness |
| Expression |
Cerebral [cortex](/brain-regions/cortex), Cochlea, Liver, Heart |
JAG1 (Jagged 1), also known as CD339, is a critical member of the Notch ligand family that plays essential roles in cell fate determination, embryonic development, tissue homeostasis, and increasingly recognized functions in neurodegeneration. Located on chromosome 20p12.2, this gene encodes a 1,218-amino acid transmembrane protein that serves as a ligand for Notch receptors (NOTCH1-4), triggering canonical Notch signaling cascades that influence gene expression programs throughout development and adult life[^berezov2012].
The JAG1-Notch axis has garnered significant attention in neurodegeneration research due to its involvement in Alzheimer's disease pathogenesis, neurogenesis regulation, neuroinflammation, and synaptic plasticity. Elevated JAG1 expression has been documented in Alzheimer's disease brains, and the protein interfaces with amyloid-beta pathology, tau pathology, and neuronal survival pathways. Beyond AD, JAG1 has relevance to other neurodegenerative conditions and developmental disorders, making it a significant node at the intersection of developmental biology and age-related neurodegeneration[^lau2020].
¶ Gene and Protein Structure
| Feature |
Details |
| Gene Symbol |
JAG1 (CD339, JAG1, Serrate-1) |
| Full Name |
Jagged 1 |
| Chromosomal Location |
20p12.2 |
| NCBI Gene ID |
1950 |
| OMIM |
184756 |
| Ensembl ID |
ENSG00000101384 |
| UniProt |
P78504 |
| Protein Length |
1,218 amino acids |
| Molecular Weight |
~134 kDa |
¶ Protein Domain Architecture
JAG1 is a type I transmembrane protein with complex domain organization:
- N-terminal signal peptide (aa 1-20): Directs protein to secretory pathway
- DSL domain (aa 45-100): Delta-Serrate-Lag domain critical for Notch binding
- Multiple EGF-like repeats (aa 100-650): 16 EGF-like repeats mediating receptor interaction specificity
- Cysteine-rich region (aa 650-800): Maintains proper protein folding
- Transmembrane domain (aa 800-825): Single pass membrane anchor
- Cytoplasmic tail (aa 825-1218): Intracellular signaling functions
The extracellular domain undergoes proteolytic cleavage (S1 cleavage) to produce a soluble form, and the remaining membrane-bound fragment can undergo S2 cleavage by ADAM proteases to release the intracellular domain (NICD) for nuclear signaling.
Multiple JAG1 isoforms have been described:
- Full-length transmembrane isoform (canonical)
- Soluble isoforms generated by alternative splicing or proteolysis
- Cell-type specific isoforms with distinct signaling properties
JAG1 activates Notch receptors through cell-cell contact:
flowchart TD
A["JAG1<br/>Ligand"] --> B["NOTCH Receptor"]
B --> C["S1 Cleavage<br/>Ligand-independent"]
A --> D["Notch-Dependent<br/>Activation"]
D --> E["S2 Cleavage<br/>ADAM Protease"]
E --> F["S3 Cleavage<br/>γ-Secretase"]
F --> G["NICD<br/>Intracellular"]
G --> H["CSL Complex"]
H --> I["Target Gene<br/>Transcription"]
I --> J["Cell Fate<br/>Differentiation"]
Notch Receptor Family:
- NOTCH1: Ubiquitous expression, diverse functions
- NOTCH2: Brain, immune system
- NOTCH3: Vascular smooth muscle, CNS
- NOTCH4: Endothelial cells
Canonical Notch Signaling:
- JAG1 binds Notch receptor on adjacent cell
- S2 cleavage releases extracellular fragment
- S3 cleavage (γ-secretase) releases NICD
- NICD translocates to nucleus
- Forms complex with CSL (RBPJ) and co-activators
- Transcribes Hes, Hey, and other target genes
Non-canonical Pathways:
- Notch interactions with other receptors
- JAG1-independent Notch activation
- Cross-talk with Wnt, Hedgehog, BMP pathways
JAG1 has emerged as a significant player in AD pathogenesis[berezov2012][chen2023]:
1. Amyloid-Beta Interaction
- JAG1 expression elevated in AD brain
- Aβ enhances JAG1 expression in neurons and glia
- JAG1-Notch signaling intersects with APP processing
- NICD generation modified by Aβ exposure
2. Tau Pathology
- Notch signaling affects tau phosphorylation
- JAG1 modulates tau-related gene expression
- Potential cross-talk in neurofibrillary tangle formation
3. Neuroinflammation
- JAG1 in microglial activation
- Notch-mediated cytokine production
- Neuroinflammatory amplification loop[^song2022]
4. Synaptic Dysfunction
- Notch regulates synaptic plasticity genes
- JAG1-Notch affects LTP and memory formation
- Contributes to early synaptic deficits
5. Neurogenesis Impact
- Adult hippocampal neurogenesis impaired in AD
- JAG1-Notch affects neural stem cell fate
- Links to cognitive decline
Though less studied, JAG1 has relevance to PD:
1. Dopaminergic Development
- Notch signaling in dopaminergic neuron specification
- JAG1 expression in substantia nigra
- May affect neuronal survival
2. Alpha-Synuclein Pathology
- Notch activation influences α-synuclein aggregation
- Potential cross-talk in synucleinopathy
- Neuronal vulnerability modulation
3. Neuroinflammation
- Microglial Notch signaling in PD
- JAG1 in inflammatory responses
In ALS, JAG1 contributes through:
1. Motor Neuron Development
- Notch in motor neuron specification
- Altered JAG1 expression in ALS
- Developmental vulnerability
2. Glial-Neuronal Communication
- Astrocytic JAG1 affecting motor neurons
- Non-cell autonomous toxicity
- Notch-mediated signaling inglia
- Huntington's Disease: Notch in striatal neuron function
- Multiple Sclerosis: JAG1 in demyelination
- Stroke: Notch in ischemia response
| Brain Region |
Expression Level |
Notes |
| Hippocampus |
High |
CA1-CA3, dentate gyrus |
| Cerebral Cortex |
High |
Layer 5 pyramidal neurons |
| Subventricular Zone |
High |
Neural stem cells |
| Substantia Nigra |
Moderate |
Dopaminergic neurons |
| Cerebellum |
Moderate |
Purkinje cells |
- Neurons: High expression, particularly pyramidal neurons
- Astrocytes: Moderate, increases with activation
- Microglia: Inducible expression under stress
- Oligodendrocytes: Lower expression
- Neural Stem Cells: High for fate decisions
JAG1 is widely expressed outside the CNS:
- Cochlea: Inner ear development, deafness in Alagille
- Vascular system: Angiogenesis
- Liver: Bile duct development
- Heart: Valve formation
| Receptor |
Interaction |
Primary Functions |
| NOTCH1 |
Primary |
Diverse, ubiquitous |
| NOTCH2 |
Strong |
Brain, immune |
| NOTCH3 |
Moderate |
Vascular, CNS |
| NOTCH4 |
Weaker |
Endothelial |
¶ Co-factors and Modulators
- DLL ligands: JAG1 co-operates with DLL1, DLL4
- Fringe proteins: Modify JAG1-Notch specificity
- ADAM proteases: S2 cleavage (TACE/ADAM17)
- γ-secretase: S3 cleavage (presenilins)
HES/HEY Family:
- HES1, HES5: Master regulators
- HEY1, HEY2: Cardiovascular, neuronal
Other Targets:
- Cyclin D1 (cell cycle)
- c-Myc (proliferation)
- NF-κB components
- Notch1 itself (feedback)
Modulating JAG1-Notch offers therapeutic potential[^chen2023]:
1. γ-Secretase Inhibitors
- Prevent NICD generation
- Clinical trials in AD (failed, too broad)
- Next-gen selective inhibitors
2. Notch Receptor Modulators
- Monoclonal antibodies against Notch
- Engineered decoy receptors
- Small molecule modulators
3. JAG1-Specific Approaches
- JAG1 neutralizing antibodies
- Peptide blockers of JAG1-Notch interaction
- Soluble JAG1 for pathway modulation
- Developmental toxicity: Notch inhibition affects many processes
- Bidirectional effects: Both protective and pathogenic roles
- Selectivity: JAG1 vs. other ligands
- CNS delivery: Blood-brain barrier challenges
- Antibody-based therapies
- Small molecule γ-secretase modulators
- Natural compounds affecting Notch
- Gene therapy targeting JAG1
- Alagille Syndrome: ~40% caused by JAG1 mutations
- Tetralogy of Fallot: Associated variants
- Deafness: Cochlear expression variants
- No strong AD-associated JAG1 variants
- Expression quantitative trait loci (eQTLs)
- Potential modifier effects
- How does JAG1-Notch specifically contribute to AD vs. normal aging?
- What determines protective vs. pathogenic signaling?
- Can selective modulation avoid developmental toxicity?
- Are there therapeutic windows for intervention?
- Single-cell Notch pathway analysis
- Structure-based inhibitor design
- Brain-penetrant Notch modulators
- Combination with anti-Aβ therapies